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RAS-like (RAL) GTPases function in Wnt signalling-dependent intestinal stem cell 16 
proliferation and regeneration. Whether RAL proteins work as canonical RAS 17 
effectors in the intestine, and the mechanisms of how they contribute to 18 
tumourigenesis remain unclear. Here, we show that RAL GTPases are necessary 19 
and sufficient to activate EGFR/MAPK signalling in the intestine, via induction of 20 
EGFR internalisation. Knocking down Drosophila RalA from intestinal stem and 21 
progenitor cells leads to increased levels of plasma membrane-associated EGFR 22 
and decreased MAPK pathway activation. Importantly, in addition to impacting stem 23 
cell proliferation during damage-induced intestinal regeneration, this role of RAL 24 
GTPases impacts on EGFR-dependent tumorigenic growth in the intestine and in 25 
human mammary epithelium. However, the effect of oncogenic RAS in the intestine 26 
is independent from RAL function. Altogether, our results reveal previously 27 
unrecognised cellular and molecular contexts where RAL GTPases become 28 
essential mediators of adult tissue homeostasis and malignant transformation. 29 
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The precise spatial and temporal regulation of signalling pathway activity is essential 34 
for organ development and adult tissue homeostasis. The latter is particularly 35 
important in stem cell maintained self-renewing epithelia, such as that of the 36 
gastrointestinal tract (Richardson et al., 2014), where cell loss needs to be 37 
counteracted by stem cell proliferation and differentiation while limiting the potential 38 
for unwanted overgrowth (Radtke and Clevers, 2005). Progressive loss of control 39 
over proliferative pathways either through loss of tumour suppressor genes or the 40 
activation of oncogenes are associated with tumour development and progression 41 
(Hanahan and Weinberg, 2011). 42 
Regulation of intestinal homeostasis involves the coordinated action of multiple 43 
evolutionarily conserved signalling pathways, which relay environmental and niche-44 
derived signals to stem cells to ultimately determine their activity (Gehart and 45 
Clevers, 2019; Nászai et al., 2015; Scoville et al., 2008). Increasing understanding of 46 
how these pathways are regulated not only provides insight into basic stem cell 47 
biology, but also sheds light onto pathological conditions often associated with 48 
uncontrolled stem cell proliferation, such as cancer (Biteau et al., 2011; Sell, 2010). 49 
Epidermal growth factor receptor (EGFR, also known as ErbB1 or HER1) is a 50 
member of the ErbB family of growth factor receptors, which play essential roles in 51 
regulating cell proliferation, differentiation and survival (Citri and Yarden, 2006; Wee 52 
and Wang, 2017). In the mammalian intestinal epithelium, EGFR is highly expressed 53 
in intestinal stem cells (ISC) and transit amplifying cells (Yang et al., 2017). EGFR 54 
ligands, such as EGF, are released by Paneth cells and the mesenchyme and are 55 
required for the maintenance and proliferation of ISCs (Dvořák et al., 1994; Jardé et 56 
al., 2020; Poulsen et al., 1986). Ectopic activation of EGFR signalling in the intestine 57 
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by luminal application or genetic overexpression of pathway ligands (Bongers et al., 58 
2012; Kitchen et al., 2005; Marchbank et al., 1995), or deletion of the negative 59 
regulator leucine-rich repeats and immunoglobulin-like domains protein 1 (Lrig1) 60 
(Powell et al., 2012; Wong et al., 2012), leads to elevated ISC proliferation. On the 61 
other hand, loss of EGFR signalling induces quiescence of Lgr5+ ISCs in vitro 62 
(Basak et al., 2017). 63 
Gene amplification and activating point mutations of EGFR are highly prevalent in  64 
cancer (Santarius et al., 2010; Yarden and Pines, 2012). Ectopic EGFR/Ras/MAPK 65 
signalling is thought to be an early step in colorectal cancer (CRC) development 66 
(Calcagno et al., 2008). Hyperactivation of the pathway accelerates intestinal 67 
tumourigenesis driven by Adenomatous polyposis coli loss (Apcmin/+ mice) (Luo et al., 68 
2009), while a genetic background of partial loss-of-function of EGFR (Roberts et al., 69 
2002) or small molecule inhibitor treatment reduce cancer incidence (Roberts et al., 70 
2002; Torrance et al., 2000). 71 
The Drosophila intestinal epithelium shares remarkable homology with its 72 
mammalian counterpart. The tissue is maintained by ISCs that replenish the 73 
epithelium through progenitor cells called enteroblasts (EB), which differentiate into 74 
either secretory enteroendocrine (EE) cells or absorptive enterocytes (ECs) 75 
(Micchelli and Perrimon, 2006; Ohlstein and Spradling, 2006). Importantly, signalling 76 
pathways governing intestinal proliferation and differentiation are highly conserved 77 
between fruit flies and mammals (Nászai et al., 2015; Miguel Aliaga et al., 2018). 78 
Activation of EGFR/Ras/MAPK within ISCs by niche-derived EGF-like ligands is 79 
essential to sustain homeostatic and regenerative proliferation of the adult fly midgut, 80 
while constitutive pathway activation in ISCs is sufficient to drive intestinal 81 
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hyperplasia (Biteau and Jasper, 2011; Buchon et al., 2010; Jiang et al., 2011; Xu et 82 
al., 2011). 83 
Regulation of EGFR signalling activity is highly dependent on various modes of 84 
receptor trafficking throughout the endocytic pathway. Indeed, abnormal trafficking of 85 
receptor tyrosine kinases is linked to cancer (Lanzetti and Di Fiore, 2017; Mosesson 86 
et al., 2008). Following internalization through Clathrin-mediated (CME) or Clathrin-87 
independent endocytosis (CIE) (Sorkin and Goh, 2009), EGF ligand/receptor 88 
complexes can either be targeted for recycling into the plasma membrane (PM), or 89 
ubiquitinated and targeted to late endosomes for lysosomal degradation (Sigismund 90 
et al., 2008, 2013). Most recently, autophagy has emerged as an important 91 
mechanism implicated in the termination of EGFR/MAPK signalling in the intestine 92 
(Zhang et al., 2019). While endocytosis is classically considered as a process to 93 
terminate pathway activity (Tomas et al., 2014), significant evidence suggests that 94 
receptors retain their ability to relay their signal even after internalisation, hence 95 
signalling is not limited to the PM (Sadowski et al., 2009). The relative contribution of 96 
PM versus intracellular EGFR to downstream signalling in vivo remains unclear 97 
(Sousa et al., 2012; Teis et al., 2006). 98 
RAL small GTPases are best recognised for their role as effectors of Ras signalling, 99 
which has attracted basic and translational research into their potential in cancer 100 
development and progression (Moghadam et al., 2017). Mammalian RAL GTPases, 101 
RALA and RALB, have well characterized roles in membrane trafficking through their 102 
involvement in the exocyst complex (Bodemann and White, 2008; Chen et al., 2007; 103 
Chien et al., 2006) and in the regulation of clathrin (Jullien-Flores et al., 2000) and 104 
caveolar-dependent endocytosis (Jiang et al., 2016). RAL signalling is potentiated by 105 
RALGEFs, and negatively regulated by RALGAPs (Neel et al., 2011). RALGEF, such 106 
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as RALGDS, can be activated upon association with oncogenic RAS (Koyama and 107 
Kikuchi, 2001) and mediate Ras-driven skin tumourigenesis (González-García et al., 108 
2005). 109 
We recently identified a novel role of RAL GTPases in the regulation of Wnt 110 
signalling activity in ISCs through the regulation of Wnt receptor trafficking into 111 
intracellular compartments (Johansson et al., 2019). The relevance of RAL GTPases 112 
in intestinal tumourigenesis remained unaddressed as their function in the intestine 113 
became redundant upon loss of Apc, a key driver of CRC (Johansson et al., 2019). 114 
Furthermore, whether RAL proteins (RALs) can impact intestinal biology beyond Wnt 115 
signalling and through their classical role as Ras effectors is unclear.  116 
Here, using the Drosophila intestine and human lung and breast cancer cell lines we 117 
uncover an important role of RAL GTPases activating EGFR/MAPK signalling-driven 118 
cell proliferation, through induction of EGFR internalization. Our results show that, 119 
while RAL inhibition is an efficient means of attenuating intestinal hyperplasia caused 120 
by constitutively active forms of EGFR, the effect of oncogenic Ras in the intestine is 121 
insensitive to attenuation of RAL function. Our findings support a positive role of 122 
receptor tyrosine kinase internalization in signalling activation in vivo and identify 123 
physiological and pathological settings highly sensitive to the presence of RAL 124 
proteins, which may provide ideal platforms for the development of therapeutic 125 
approaches geared towards the modulation of RAL function. 126 




RAL GTPases are necessary for EGFR/MAPK signalling activation following 129 
damage to the intestinal epithelium 130 
We have previously demonstrated that RalA, the single Ral gene in Drosophila, is 131 
required for Wnt signalling activation in the developing Drosophila wing and adult 132 
midgut (Johansson et al., 2019). A canonical role of RalA as RAS effector remained 133 
unaddressed. 134 
EGFR/Ras signalling is an important determinant of wing tissue patterning (Wang, 135 
2000; Zecca and Struhl, 2002) and ISC proliferation in the adult Drosophila midgut 136 
(Biteau and Jasper, 2011; Buchon et al., 2010; Jiang et al., 2011; Xu et al., 2011). 137 
We observed that adult wings resulting from RNAi driven knockdown of RalA using 138 
the engrailed-gal4 driver (en>RalA-RNAi), showed a more severely dysmorphic 139 
phenotype than that caused by wingless knockdown (en>wg-RNAi) or EGFR 140 
knockdown (en>EGFR-RNAi) only (Figure 1A, B). Instead, adult wings from 141 
en>RalA-RNAi animals displayed a dysmorphic phenotype more similar to that 142 
resulting from combined knockdown of both wg and EGFR downregulation (en>wg-143 
RNAi + EGFR-RNAi) (Figure 1A, B). These results led us to hypothesize that RalA 144 
may regulate pathways other than Wnt signalling, including EGFR/Ras signalling. To 145 
address this, we turned to the adult Drosophila midgut, a robust paradigm for the 146 
study of signal transduction in adult tissue homeostasis, where RalA plays a pivotal 147 
role (Johansson et al., 2019). 148 
RalA is required within ISCs to induce adult midgut regeneration following damage 149 
by oral infection with Erwinia carotovora carotovora 15 (Ecc15) (Johansson et al., 150 
2019). To achieve a global view of intestinal pathways affected by RalA, we 151 
8 
 
performed a transcriptomic analysis by RNAseq of whole midguts from vehicle 152 
treated (Mock) or damaged (Ecc15 fed) control animals or following adult restricted 153 
RalA knockdown in intestinal stem and progenitor cells using the escargot-gal4 154 
driver (ISC/EB>) (Micchelli and Perrimon, 2006). Consistent with its effect on ISC 155 
proliferation (Johansson et al., 2019), RalA knockdown significantly impaired 156 
damage-induced upregulation of cell cycle genes in the midgut (Figure 1C). 157 
Additionally, levels of genes associated with the EGFR/MAPK pathway, such as 158 
argos (aos), rhomboid (rho), Sox21a and string (stg) appeared increased following 159 
Ecc15 infection in control midguts, in a RalA dependent manner (Figure 1C). RT-160 
qPCR confirmed RNAseq results on rho, a well-characterized activator of 161 
EGFR/MAPK signalling in ISCs (Liang et al., 2017; Ngo et al., 2020), and two 162 
downstream targets of the pathway required for ISC proliferation, Sox21a and stg 163 
(Jin et al., 2015; Meng and Biteau, 2015) (Figure 1D). Furthermore, 164 
immunofluorescence staining for the transcription factor Sox21a (Meng and Biteau, 165 
2015) and the activated form of the MAPK, phosphorylated ERK (pERK), in control 166 
animals and following RalA knockdown from ISCs/EBs confirmed the need for RalA 167 
for upregulation of MAPK signalling and downstream targets following damage to the 168 
midgut (Figure 1E-H and Figure 1—figure supplement 1A-D). Together, these results 169 
suggest that RalA is necessary for damage-induced EGFR/MAPK signalling 170 
activation in the Drosophila adult midgut. 171 
Previously, we showed that the role of RAL proteins in Wnt signalling activation and 172 
intestinal regeneration is conserved between Drosophila and mice (Johansson et al., 173 
2019). The mouse intestine has a robust capacity to regenerate following damage by 174 
gamma irradiation, as demonstrated by an increase in the number of regenerating 175 
crypts 72 h following irradiation (Cordero et al., 2014; Johansson et al., 2019). We 176 
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next assessed whether MAPK activation in the regenerating mouse intestine 177 
required RAL GTPases. Single conditional knockout of either Rala (Ralafl/fl) or Ralb 178 
(Ralbfl/fl) in the murine intestinal epithelium using the Villin-CreER driver impaired 179 
ERK activation in regenerating intestines when compared to control (VillinCreER) 180 
(Figure 1I, J and Figure 1—figure supplement 1E). Therefore, RAL GTPases' 181 
requirement for EGFR/MAPK pathway activation in the intestinal epithelia is 182 
evolutionarily conserved between fruit flies and mammals. 183 
RAL GTPases are sufficient for EGFR/MAPK signalling activation in the 184 
Drosophila midgut 185 
Ectopic expression of wild type RalA in ISC/EB is sufficient to induce Wnt pathway 186 
activation and intestinal proliferation in the Drosophila midgut (Johansson et al., 187 
2019). To determine whether RalA is also sufficient to induce EGFR/MAPK 188 
signalling, we assessed Sox21a (Figure 1K, L), pERK (Figure 1M, N) and total ERK 189 
(Figure 1—figure supplement 1F, G) levels by immunostaining following RalA 190 
overexpression in midgut ISCs/EBs. While levels of Sox21a and pERK were 191 
increased in RalA overexpressing midguts compared to wild type control ones 192 
(Figure 1K-N), total levels of ERK in the midgut remained unchanged across 193 
genotypes (Figure 1—figure supplement 1F, G). Immunostaining results for ERK and 194 
pERK were confirmed by western blot (Figure 1—figure supplement 1H) and are 195 
consistent with ERK activation and not total protein levels being increased upon 196 
midgut injury (Figure 1—figure supplement 1H-J). Altogether, our data suggest that 197 
RAL GTPases are necessary and sufficient for EGFR/MAPK pathway activation 198 
within the intestinal epithelium. 199 
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RalA activation is necessary for ISC proliferation in Drosophila 200 
Small GTPases cycle between two alternative conformations: inactive (GDP-bound) 201 
and active (GTP-bound). The balance between these states is determined by the 202 
activity of guanine nucleotide exchange factors (GEF) and GTPase activating 203 
proteins (GAP), which activate and inactivate GTPases, respectively (Neel et al., 204 
2011). There are seven Ral GEFs in the human genome, RALGDS, RALGPS1-2 and 205 
RGL1-4, which are often found misregulated in cancer (González-García et al., 2005; 206 
Koyama and Kikuchi, 2001; Rodriguez-Viciana and McCormick, 2005) and are 207 
considered emerging therapeutic targets (Neel et al., 2011; Vigil et al., 2010). 208 
However, the in vivo role of RAL GEFs in the intestine remains unknown. Several Ral 209 
GEFs are conserved in Drosophila (Gentry et al., 2014): Rgl, GEFmeso and CG5522 210 
(RalGPS). Rgl is a close orthologue of mammalian RGL (Mirey et al., 2003), 211 
GEFmeso was identified in a yeast two hybrid screen using active RalA as bait 212 
(Blanke and Jäckle, 2006), while CG5522 was identified based on its close homology 213 
to mammalian RalGPS1 (Hu et al., 2011). 214 
We next tested the functional role of each of these Ral GEFs in the fly midgut though 215 
RNAi-driven targeted knockdown and assessment of their impact on intestinal 216 
regeneration following oral infection with Ecc15 (Basset et al., 2000). The 217 
regenerative capacity of the adult posterior midgut (R4-R5) was quantified as per the 218 
number of proliferating ISCs, identified by staining with phosphorylated histone H3 219 
antibody (pH3). As expected, Ecc15 infection induced significant increase in ISC 220 
proliferation relative to mock-treated control animals (Figure 2A-D). Knocking down 221 
either of the three Ral GEFs of interest significantly impaired regenerative ISC 222 
proliferation in the midgut (Figure 2A-D) to levels comparable to those observed upon 223 
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RalA knockdown (Johansson et al., 2019). Furthermore, Ral GEF knockdown led to a 224 
significant reduction in MAPK activation in the midgut following damage (Figure 2E, 225 
F). These results provide evidence highlighting the importance of maintaining the 226 
active status of RalA for robust stem cell proliferation and MAPK activation in the 227 
intestine. 228 
RalA regulates EGFR- but not oncogenic Ras-driven hyperplasia in the 229 
intestine 230 
During our initial assessment of genetic interactions between EGFR signalling and 231 
RalA in adult wings, we observed that constitutive overexpression of EGFR under 232 
engrailed-gal4 (en>EGFRwt) caused sever organismal lethality, which was greatly 233 
suppressed by concomitant knockdown of RalA (Figure 3—figure supplement 1A). 234 
Wing vein patterning defects observed in rare en>EGFRwt adult escapers, was also 235 
suppressed by RalA knockdown (Figure 3—figure supplement 1B). These results 236 
reinforced the importance of RalA as a broad mediator of EGFR signalling.  237 
EGFR is overexpressed in ~20% of breast and ~80% of CRCs (Rimawi et al., 2010; 238 
Spano et al., 2005), and activating mutations of Ras are one of the most common 239 
cancer-associated genetic alterations (Prior et al., 2012). Activation of the 240 
EGFR/MAPK pathway in the adult Drosophila midgut by ISC/EB-specific 241 
overexpression of wild type EGFR (EGFRWT) or constitutively active Ras (RasV12) 242 
was sufficient to induce intestinal hyperproliferation (Figure 3A, B) (Jiang et al., 2011; 243 
Zhang et al., 2019). Downregulation of RalA suppressed EGFRWT- but not RasV12-244 
driven ISC hyperproliferation (Figure 3A, B and Figure 3—figure supplement 1C, D). 245 
Consistently, RalA knockdown impaired activation of ERK following EGFRwt, but not 246 
RasV12 overexpression (Figure 3C, D and Figure 3—figure supplement 1E, F). 247 
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RalA potentiates EGFR signalling activity downstream of ligand binding 248 
Increasing the pool of receptors available for ligand binding, such as through 249 
recycling of intracellular receptor towards the plasma membrane or inhibition of 250 
receptor degradation, favours activation of receptor tyrosine kinase signalling, 251 
including EGFR (von Zastrow and Sorkin, 2007; Zhang et al., 2019). Therefore, one 252 
possible mechanism by which RAL proteins may potentiate EGFR signalling in the 253 
intestine is by facilitating ligand/receptor interactions. In that case, ligand-254 
independent, constitutively active forms of EGFR, which are linked to cancer (Endres 255 
et al., 2014), should be insensitive to RAL deficiency. To test this prediction, we co-256 
expressed RalA-RNAi with two active mutant forms of EGFR — EGFRλtop and 257 
EGFRA887T — in Drosophila intestinal stem and progenitor cells (Figure 3E, F). 258 
EGFRλtop includes an extracellular dimerization domain that causes receptor 259 
activation even in the absence of ligand (Queenan et al., 1997), and EGFRA887T 260 
contains an activating point mutation in the receptor kinase domain (Lesokhin et al., 261 
1999). Importantly, overexpression of EGFRλtop or EGFRA887T led to ISC 262 
hyperproliferation levels comparable to those observed following RasV12 263 
overexpression (Figure 3E, F compare with Figure 3A, B and Figure 3—figure 264 
supplement 1C, D). However, unlike in the case of RasV12, knocking down RalA 265 
significantly impaired EGFRλtop- or EGFRA887T-driven ISC proliferation (Figure 3E, F). 266 
Consistently, EGFRλtop- or EGFRA887T-dependent ERK activation was also 267 
suppressed by RalA-RNAi (Figure 3G, H). These results suggest that RalA 268 
influences EGFR signalling activity downstream of ligand/receptor binding. 269 
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RAL GTPases are required for EGFR internalisation 270 
RAL GTPases are key mediators of Ras-regulated membrane trafficking (Bodemann 271 
and White, 2008; Chen et al., 2007; Chien et al., 2006; Jiang et al., 2016; Jullien-272 
Flores et al., 2000). We next asked whether, as in the case of the Wnt receptor 273 
Frizzled (Johansson et al., 2019), RAL GTPases may induce EGFR/MAPK signalling 274 
through regulation of EGFR cellular localisation in the intestine. We used a well-275 
established immunostaining approach (Cordero et al., 2014; Kim-Yip and Nystul, 276 
2018; Zhang et al., 2019) and a custom developed macro to visualise EGFR cellular 277 
localization in the adult Drosophila midgut (Figure 4—figure supplement 1). Firstly, 278 
we assessed EGFR localisation in control adult Drosophila midguts or following 279 
genetic manipulation of RalA expression. Knocking down RalA in ISCs/EBs led to 280 
significantly increased levels of PM-associated EGFR wild type (Figure 4A, B) and 281 
A887T mutant (Figure 4C, D). Conversely, overexpression of wild type RalA 282 
decreased membrane localisation of EGFR (Figure 4E, F). We were unable to 283 
assess impact of knocking down RalA on EGFRλtop localization as our antibody, 284 
designed to bind the extracellular domain of EGFR, failed to recognise this mutant 285 
version of the receptor. Consistent with the role of RAL GTPases as effectors of Ras, 286 
knocking down endogenous Ras from ISCs/EBs caused a similar effect on EGFR 287 
localization than that observed upon RalA downregulation (Figure 4—figure 288 
supplement 2). Altogether, these results strongly suggest that activation of RalA 289 
induces EGFR/MAPK signalling in the intestine by increasing the intracellular pool of 290 
EGFR. Consequently, oncogenic Ras, whose activation is independent of EGFR 291 
signalling, is refractory to RalA function in the intestine (Figure 3A-D and Figure3—292 
figure supplement 1C, D).  293 
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Next, we used a surface biotinylation-based biochemical assay to directly quantify 294 
the rate of EGFR internalization in H1299, a human non-small cell lung cancer 295 
(NSCLC) cell line with intact EGFR signalling (Amann et al., 2005). To obtain a 296 
measure of endocytosis that was not influenced by the rate at which the receptor 297 
returns, or ‘recycles’, to the cell surface from endosomes, we performed the surface 298 
biotinylation-based assay in the presence of the receptor recycling inhibitor, 299 
primaquine. This clearly indicated that EGF-driven (but not EGF-independent) 300 
endocytosis of EGFR was significantly reduced by combined knockdown of Rala and 301 
Ralb (Figure 4G and Figure 4—figure supplement 3A, B). By contrast, integrin α5β1, 302 
transferrin (hTfnR) or ligand-induced c-Met receptor internalization, were not affected 303 
by Rala/b knockdown (Figure 4—figure supplement 3C-F). These results suggest 304 
that the effect of RAL GTPases on EGFR cellular localisation is conserved between 305 
Drosophila and mammals, and that RAL proteins function in a context-dependent 306 
manner, as opposed to being generally required for transmembrane or tyrosine 307 
kinase receptor trafficking dynamics. 308 
RAL proteins are necessary for EGFR dependent tumorigenesis 309 
Given that intestinal hyperplasia caused by hyperactivation of β-Catenin or 310 
oncogenic RAS is independent of RAL proteins (Johansson et al., 2019) (Figure 3A, 311 
B; Figure 3—figure supplement 1C, D), the importance of RAL GTPases in intestinal 312 
malignancy remains unaddressed. The effect of RalA knockdown on intestinal 313 
hyperproliferation caused by overexpression of wild type or constitutively active 314 
mutants of EGFR in the intestine (Figure 3) suggests that other pathological settings 315 
driven by exacerbated EGFR activity might also be sensitive to RAL function. 316 
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c-Src is a conserved non-receptor tyrosine kinase whose expression is necessary 317 
and sufficient to drive regeneration and tumourigenesis of both the Drosophila and 318 
mouse intestine through EGFR/MAPK activation (Cordero et al., 2014; Kohlmaier et 319 
al., 2015) (Figure 5A, B). Consistently, Src overexpression in ISCs/EBs 320 
(esgts>Src64wt) induced expression of the MAPK pathway transcriptional target 321 
Sox21a (Figure 5C, D) and pERK levels (Figure 5E, F) (Cordero et al., 2014; 322 
Kohlmaier et al., 2015). Importantly, knocking down RalA (ISC/EB>Src64wt; RalA-323 
RNAi) suppressed Src-driven ISC hyperproliferation and MAPK signalling activation 324 
in the Drosophila midgut (Figure 5A-F), which correlated with an increase in 325 
membrane versus intracellular levels of EGFR in ISC/EB>Src64wt; RalA-RNAi 326 
midguts when compared to ISC/EB>Src64wt counterparts (Figure 5G, H).  327 
As a proof of principle in an orthogonal mammalian system dependent on EGFR for 328 
morphogenesis, we employed the human breast tumour cell line HMT3522 T4-2 329 
(henceforth referred to as ‘T4-2’) as a paradigm to test the role of mammalian RAL 330 
GTPases in malignant growth. T4-2 is a subline obtained after spontaneous 331 
malignant transformation of the benign breast tumour cell line HMT3522 S1 332 
(henceforth ‘S1’). Compared to the S1 predecessor, T4-2 cells grow as disorganised 333 
aggregates of cells when cultured in 3Dimensional (3D) Extracellular Matrix gels 334 
such as Matrigel. This growth and morphogenesis in 3D of T4-2 cells is EGFR-335 
dependent: T4-2 show robustly upregulated EGFR levels and activation, their growth 336 
is independent of exogenous EGF, and they are acutely sensitive to EGFR inhibitors 337 
(Madsen et al., 1992; Wang et al., 1998). Thus, we hypothesised that T4-2 growth 338 
would be dependent on RAL function. 339 
Consistent with previous reports (Madsen et al., 1992; Wang et al., 1998), treating 340 
T4-2 cells with two structurally independent EGFR inhibitors, Tyrphostin (AG1478) 341 
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and Erlotinib, resulted in defective growth as determined by a reduction in 3D acinus 342 
size (Figure 5I, J). Importantly, stable depletion of Rala or Ralb in T4-2 by shRNA 343 
(Figure 5K, L—figure supplement 1A, B) phenocopied EGFR inhibition, as 344 
determined by a significant reduction in 3D acinus size (Figure 5K, L). Therefore, 345 
RALA/B function is similarly required for a mammalian morphogenetic function that is 346 
dependent on EGFR. Altogether, our results uncover a conserved role of RAL 347 
GTPases mediating EGFR/MAPK-dependent tissue homeostasis and 348 
transformation.  349 
Discussion 350 
Spatial and temporal regulation of signal transduction by the endocytic pathway 351 
plays a key role in health and pathophysiology (Casaletto and McClatchey, 2012; 352 
von Zastrow and Sorkin, 2007). The impact of this process in adult stem cells and 353 
tissue homeostasis is only recently becoming evident from reports on the effect of 354 
endocytosis and autophagy on ISC proliferation through modulation of Wnt/β-355 
Catenin and EGFR/MAPK activity, respectively (Johansson et al., 2019; Zhang et al., 356 
2019).  357 
In this study, we identify a role for the Ras-related protein RAL in the activation of 358 
EGFR/MAPK signalling activity through regulation of EGFR internalisation (Figure 6). 359 
Preventing RAL function in Drosophila intestinal stem/progenitor cells reduces the 360 
intracellular pool of EGFR, leading to decreased MAPK activation and downstream 361 
signalling. This role of RAL proteins impacts stem cell proliferation and regeneration 362 
of the intestinal epithelium and has implications in pathological settings that depend 363 
on active EGFR signalling, including intestinal hyperplasia and breast cancer cell 364 
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growth. However, oncogenic Ras expression in the intestine escapes the anti-365 
proliferative effect of Ral knockdown. 366 
RAL GTPases as regulators of signal transduction 367 
While internalization is recognised as the initial means to attenuate signal 368 
transduction through reduction of plasma membrane receptors available for 369 
activation by extracellular ligands (Goh et al., 2010; Sousa et al., 2012; Vieira et al., 370 
1996; von Zastrow, 2003), the subsequent outcome of endocytosis on signalling is 371 
dependent on the trafficking pathway followed by internalised receptors. 372 
Internalisation of membrane EGFR through Clathrin-mediated endocytosis results in 373 
prolonged EGFR signalling by favouring receptor recycling back to the plasma 374 
membrane, while Clathrin-independent endocytosis leads to EGFR degradation and 375 
signalling attenuation (Sigismund et al., 2008). The differential effect of endocytic 376 
trafficking on EGFR has therapeutic implications as Clathrin inhibition can divert a 377 
tyrosine kinase inhibitor-resistant forms of EGFR from Clathrin-mediated endocytosis 378 
and recycling to pinocytosis and degradation in non-small cell lung carcinoma 379 
(Ménard et al., 2018). 380 
Here, we provide robust evidence of physiological and pathological contexts in the 381 
intestine where the internalisation of EGFR mediated by RAL GTPases directly 382 
correlates with potentiation of downstream MAPK signalling (Figure 6). We recently 383 
reported a similar effect of RAL proteins on the seven transmembrane class 384 
receptor, Frizzled, leading to high threshold of Wnt signalling activity (Johansson et 385 
al., 2019). In both cases, the ultimate outcome of RAL action is an efficient acute 386 
proliferative response of intestinal stem cells during tissue regeneration following 387 
damage. Therefore, RAL GTPases are effectors of two pivotal signal transduction 388 
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pathways within the intestinal epithelium (Biteau and Jasper, 2011; Buchon et al., 389 
2010; Jardé et al., 2020; Jiang et al., 2011; Perochon et al., 2018; Sato et al., 2009; 390 
Xu et al., 2011). The effect of knocking down RalA in the Drosophila midgut is, 391 
however, milder than that observed upon individual or combined impairment of 392 
Wnt/β-Catenin and EGFR/MAPK signalling reception in ISCs (Xu et al., 2011). This 393 
suggests that RalA is only partly responsible for the activation of these signalling 394 
pathways and its effect is only evident in the regenerative response to damage, 395 
which requires high thresholds of signalling activity to allow acute stem cell 396 
proliferation for tissue regeneration. The scenario is different in the mammalian 397 
intestine, where combined knockout of Rala and Ralb leads to complete disruption of 398 
intestinal epithelial homeostasis (Johansson et al., 2019). This may relate to inherent 399 
differences in the signalling activity levels needed to maintain homeostatic ISC 400 
proliferation in the fly midgut versus the mouse intestine. Compared to its murine 401 
counterpart, basal proliferation in the adult fly midgut is relatively low and there is no 402 
transit amplifying proliferative zone (Micchelli and Perrimon, 2006; Ohlstein and 403 
Spradling, 2006). Alternatively, the difference could lie in the different experimental 404 
approaches taken, namely the use of gene knockout in the mouse versus partial 405 
knockdown in the fly. Our efforts to generate FRT mediated Rala knockout clones in 406 
the adult Drosophila midgut were unsuccessful (data not shown) and full mutant 407 
animals are not viable. Therefore, any potential residual activity due to incomplete 408 
knockdown could lead to milder Drosophila phenotypes. 409 
RAL GTPases have been linked to Clathrin-mediated endocytosis via interaction of 410 
their effector protein, RAL binding protein (RALBP1), with the Clathrin adaptor AP2 411 
(Jullien-Flores et al., 2000). More recently, RAL proteins have also been shown to 412 
engage in Caveolin-mediated endocytosis (Jiang et al., 2016). While the potentiating 413 
19 
 
effect of RALs on EGFR signalling activity would favour a role of the small GTPases 414 
in Clathrin-mediated endocytosis in the system, this needs to be directly assessed. 415 
Experiments to functionally connect RalA with specific endocytic trafficking pathways 416 
using Drosophila genetics have been unsuccessful as, consistent with recently 417 
published work (Zhang et al., 2019), global perturbation of the trafficking machinery 418 
within ISCs leads to very severe disruption of intestinal homeostasis (data not 419 
shown), precluding the establishment of meaningful genetic interactions. 420 
Future research will need to be done to better elucidate the place of action of RAL 421 
GTPases within the endocytic trafficking pathway and its connection with EGF and 422 
Wnt receptors in the intestine. The use of fluorescently tagged endocytic proteins 423 
(Dunst et al., 2015) combined with recently developed live imaging approaches in 424 
the adult Drosophila intestine (Koyama et al., 2020; Martin et al., 2018) offers a clear 425 
opportunity to visualise spatial and temporal receptor/endosome interactions in vivo. 426 
RAL GTPases as potential therapeutic targets in cancer 427 
EGFR function is frequently altered in cancer (Santarius et al., 2010; Yarden and 428 
Pines, 2012). Excessive protein levels due to gene amplification or increased-429 
transcription are the most common EGFR perturbations found in gastrointestinal and 430 
lung adenocarcinoma as well as in cholangiocarcinoma (Birkman et al., 2016; Jung 431 
et al., 2017; Li et al., 2008). On the other hand, EGFR kinase domain activating point 432 
mutations are associated with non-small cell lung carcinoma and glioblastoma, but 433 
are rarely seen in other types of cancer (Li et al., 2008; Siegelin and Borczuk, 2014; 434 
Zhang et al., 2016). Extracellular domain truncating mutations yielding to 435 
constitutively active receptor through ligand-independent dimerization have also 436 
been observed in glioblastomas (Furnari et al., 2015; Guo et al., 2015; Huang et al., 437 
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1997). We have utilised Drosophila genetic constructs that mimic all three main 438 
classes of EGFR common to human cancers and which lead to intestinal hyperplasia 439 
when overexpressed in intestinal stem/progenitor cells (Figure 3). Genetic inhibition 440 
of Ral GTPase activity consistently prevented hyperproliferation in these models, 441 
suggesting that targeting RAL function could be a potentially effective therapeutic 442 
approach in the treatment of multiple highly aggressive cancer types. 443 
Current EGFR-targeted therapies include small molecule tyrosine kinase inhibitors 444 
(TKI) and monoclonal antibodies (mAb) against the extracellular domain of the 445 
receptor (Xu et al., 2017). A number of resistance mechanisms arise secondary to 446 
treatment. Specific kinase domain mutations desensitize cells against TKI (Sequist et 447 
al., 2011; Yu et al., 2015), while alterations of the antibody binding site are observed 448 
in CRC (Arena et al., 2015). There is also a tendency for downstream mutations 449 
(Raf, Ras, MAPK, MET) to uncouple pathway activity from the receptor (Camidge et 450 
al., 2014; Mancini and Yarden, 2016). The most common form of resistance to 451 
EGFR-targeted therapies is believed to be innate rather than adaptive (Parseghian 452 
et al., 2019). Indeed, about 80% of CRCs are refractive to EGFR therapy (Bardelli 453 
and Siena, 2010). Several reports highlight how cancer cells co-opt the endocytic 454 
pathway for growth and survival benefits (Mosesson et al., 2008). In fact, these have 455 
been proposed as a potential venue for drug development (Mellman and Yarden, 456 
2013). However, based on the current evidence, we propose that targeting RAL 457 
function versus a broader component of the endocytic machinery may prove a more 458 
refined approach leading to lower toxic effects (Zhang et al., 2019).  459 
RAL effector proteins, including RALGEFs and RALBP1 have emerged as important 460 
mediators of malignant growth in pancreatic, colorectal, prostate, bladder and other 461 
tumour cell lines characterized by the presence of oncogenic RAS mutations (Neel et 462 
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al., 2011). Furthermore, genetic knockout of the RALGEF, RALGDS, ameliorates 463 
tumour growth in a mouse model of Ras-driven skin tumourigenesis (González-464 
García et al., 2005). Unexpectedly, our results show that, at least in the intestine, 465 
oncogenic mutations in Ras are refractory to Ral GTPase inhibition. These 466 
apparently discrepant results could be due to context dependent requirements for 467 
RAL function in malignancy, differences between in vitro and in vivo experimental 468 
settings and/or a potential promiscuous role of RAL effectors on small GTPase 469 
signalling.  470 
Previously, we have shown that fly and murine intestines bearing loss of Apc, a key 471 
initiating event in up to 80% of human CRC, also overcome the need for RAL 472 
GTPases to proliferate (Johansson et al., 2019). Taken together, our results argue 473 
against an effective role of anti-RAL therapies to treat CRCs carrying Apc loss of 474 
function and/or hyperactivating Ras mutations. On the other hand, tumours with 475 
overexpression or activating mutations in EGFR, such as carcinomas of the upper 476 
gastrointestinal tract, lung and mammary tissue or glioblastomas (Birkman et al., 477 
2016; Furnari et al., 2015; Guo et al., 2015; Huang et al., 1997; Li et al., 2008; 478 
Siegelin and Borczuk, 2014; Zhang et al., 2016) might be responsive to impairment 479 
of RAL function. Ultimately, taking into consideration the genetic composition of the 480 
tumour is of outmost importance when considering the use of RAL inhibition as a 481 
therapeutic approach. 482 
  483 
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Materials and Methods 484 
Key resources table is included as an Appendix. 485 
Experimental models and organisms 486 
Species used: Drosophila melanogaster, Mus musculus 487 
Only mated females were used for Drosophila experiments. 488 
Cell lines:  489 
HMT-3522 T4-2 (human breast cancer derived; from Valerie Weaver), NCI-H1299  490 
(human lung cancer derived; from ATCC), HEK293-FT (human kidney derived; from 491 
Thermo Fisher Scientific). All cell lines used in this study were authenticated through 492 
STR profiling usign Promega Geneprint 10 Kit. Gene fragment analysis was 493 
performed on a 3130xl Genetic Analyser and Genemapper v5 was used for analysis. 494 
Cell lines were confirmed negative for mycoplasma.  495 
 496 
Drosophila breeding and maintenance 497 
Flies were maintained in humidity and temperature-controlled incubators with a 12-498 
12-hour light-dark cycle. Crosses were kept at 18°C. F1s of the desired genotype 499 
were collected 2-3 days after adult eclosion and aged at 29°C for the time needed to 500 
allow for transgene activation. Only female midguts were used. Standard rearing 501 
medium used: 10g agar, 15g sucrose, 30g glucose, 15g maize meal, 10g wheat 502 
germ, 30g treacle and 10g soya flour per litre of distilled water. 503 
Exact genotypes for all figure panels are listed in Supplementary File 1. 504 
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Mouse work 505 
Mouse experiments were performed as described in (Johansson et al., 2019), 506 
according to the UK Home Office regulations and designed in accordance with the 507 
ARRIVE guidelines. Animals were fed on standard diet and water ad libitum, and 508 
under non‐barrier conditions. Genotypes used are indicated in the key resources 509 
table. Vil1CreER recombinase was induced using 80 mg/kg Tamoxifen (Sigma) 510 
IP.  Regeneration was induced using caesium-137 γ-radiation sources delivering 511 
0.423 Gy min−1 to a total of 10 Gy. Mice were sampled 3 days following 512 
irradiation damage. No distinction was made between males and females in the 513 
mouse experiments. All animals used in experiments were above 20g of weight. 514 
Experiments were performed on a C57BL/6 background and using a minimum of 515 
3 mice per condition/genotype. 516 
IHC of mouse tissue 517 
Formalin–fixed paraffin embedded (FFPE) tissues were cut into 4 µm sections and 518 
mounted onto adhesive slides, followed by a 2-hour long oven-incubation step at 519 
60C. Samples were dewaxed in xylene for 5 minutes before rehydration through 520 
serial washes in decreasing concentrations of alcohol followed by washing with H2O 521 
for 5 minutes. For heat–induced epitope retrieval sections were heated for 20 522 
minutes at 97C in Sodium Citrate pH6 retrieval buffer (Thermo, TA-250-PM1X) 523 
before cooling to 65C. This was followed by washing in Tris Buffered Saline with 524 
Tween (TBT) (Thermo, TA-999-TT). Sections were loaded onto the Dako autostainer 525 
link48 platform, washed with TBT then peroxidase blocking solution (Agilent, S2023) 526 
for 5 minutes. Sections were washed with TBT then appropriate antibody was 527 
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applied to specific slides. Phospho-p44/42 MAPK (Erk1/2) (Cell Signalling, 9101) 528 
was applied at 1/400 dilution and p44/42 MAPK (Erk1/2) (Cell Signalling 9102) was 529 
applied at 1/40 dilution for 30 minutes.  After another TBT wash, secondary antibody 530 
(Rabbit Envision, Agilent, K4003) was applied for 30 minutes before washing with 531 
TBT again. 3,3’ diaminobenzidine (Agilent, K3468) was then applied for 10 minutes 532 
before washing in H2O to terminate the reaction. Finally, slides were counterstained 533 
with haematoxylin and dehydrated in increasing concentrations of alcohol, then 534 
taken through 3 changes of xylene prior to sealing with glass coverslips using DPX 535 
mounting media for microscopy.  536 
Quantification of pERK and total ERK staining in mouse tissues 537 
A minimum of 12 and up to 30 randomly selected crypts per animal from at least 538 
three mice per genotype, per condition were quantified. Data is expressed as the 539 
percentage of crypt cells positively stained for a marker of interest per crypt. Finally, 540 
the percentage of positively stained cells was averaged for each animal. 541 
Brightfield microscopy and scoring of adult wing patterning 542 
Drosophila wings were mounted onto glass slides (VWR) with 13mm x 0.12mm 543 
spacers (Electron Microscopy Science). Images were obtained on the Zeiss Axio 544 
Observer system. Images were focus stacked using the ZEN 2 software (Zeiss). 545 
Wing dysmorphia was blindly scored on a scale from 1 to 5 using a previously 546 
developed macro 547 
https://github.com/emltwc/TracheaProject/blob/master/Blind_scoring.ijm, where 1 is 548 
a normal, wild type wing and 5 refers to the most severely disrupted adult wings. 549 
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Immunofluorescence of Drosophila tissues 550 
Immunofluorescent staining was performed as described in (Johansson et al., 2019). 551 
Briefly, tissues were dissected in PBS and immediately fixed in 4% 552 
paraformaldehyde (PFA, Polysciences Inc) at room temperature for a minimum of 30 553 
min. Once fixed, 20-minute-long washes in PBS + 0.2% Triton X-100 (PBST) were 554 
repeated three times, followed by overnight incubation at 4°C with primary antibodies 555 
in PBST + 0.5% Bovine Serum Albumin (BSA) (PBT). Prior to applying the 556 
secondary antibodies tissues were washed in PBST 3 times 20 minutes and then 557 
incubated with the appropriate antibodies in PBT for 3h at room temperature, 558 
followed by washing and mounting. 559 
Midguts stained for pERK and tERK included a methanol fixation step between PFA 560 
fixation and PBST washing steps of the standard protocol. Following PFA fixation 561 
methanol was added dropwise to the solution, with the tissues in it until the volume 562 
of the liquid is at least double. Tissues were transferred into 100% methanol for 563 
minimum 1 minute. PBS was added to the methanol dropwise to rehydrate the 564 
tissues after which the samples were subjected to the standard staining protocol. 565 
All samples were mounted onto glass slides (VWR) with 13mm x 0.12mm spacers 566 
(Electron Microscopy Science) and Vectashield antifade mounting medium 567 
containing DAPI (Vector Laboratories, Inc). Confocal images were obtained on a 568 
Zeiss LSM 780 and processed in the Zeiss ZEN software. 569 
Antibody concentrations used: anti-GFP (1:2000), anti-pERK (1:100), anti-tERK 570 
(1:100), anti-EGFR (1:50), anti-Sox21a (1:2000), anti-pH3S10 (1:100). Secondary 571 
antibodies were used as follows: anti-chicken-IgY-488 (1:200), anti-rabbit-IgG-594 572 
(1:100), anti-mouse-IgG-594 (1:100). 573 
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Drosophila midgut regeneration assay 574 
Drosophila intestinal regeneration was induced through oral infection using Erwinia 575 
carotovora subsp. carotovora 15 (Ecc15) (Basset et al., 2000), as described in 576 
(Neyen et al., 2014). Briefly, bacteria were cultured overnight in LB medium in an 577 
orbital shaker incubator at 29°C, 200 rpm. Samples were pelleted (Beckman Coulter 578 
JS-4.2 rotor, 10 min @3000rpm) and adjusted to OD600 = 200. Flies used for 579 
regeneration experiments were starved in empty vials for 2 hours prior to infection to 580 
synchronize feeding. Animals were moved into vials containing filter paper 581 
(Whatman) soaked into vehicle control, 5% sucrose solution (Mock) or the prepared 582 
bacterial solution mixed with 5% sucrose 1:1. Flies were dissected 12-16 hours after 583 
infection. 584 
Staining quantification 585 
pERK and tERK intensity were quantified in 16-bit z-stack confocal images as the 586 
average staining intensity within the GFP positive compartment. Sox21a staining 587 
was quantified in 16-bit z-stack confocal images as the average staining intensity 588 
within the entire DAPI positive compartment. pERK, tERK and Sox21a were 589 
quantified using the custom ImageJ macro: BatchQuantify 590 
(https://github.com/emltwc/2018-Cell-Stem-Cell). EGFR membrane/cytoplasmic 591 
staining was quantified in 16-bit z-stack confocal images using the custom ImageJ 592 
macro: EGFR_quant (https://github.com/emltwc/EGFRProject). 593 
Survival quantification 594 
Relative survival was calculated by counting the proportion of adult flies emerging 595 
from crosses, which carried the desired experimental genotypes, as per the 596 
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expected Mendelian ratio. When the proportion of animals of a given genotype 597 
emerged at the expected Mendelian ratio, this genotype was demed to be 100% 598 
viable.  599 
Drosophila RNA extraction, RNA-sequencing and RT-qPCR 600 
Total RNA from a minimum of 25 midguts was extracted using QIAGEN RNAeasy 601 
kit, following the manufacturer’s instructions, including the on-column DNase 602 
digestion step. For RNA-seq, an RNA integrity score was determined (average = 9.4, 603 
SD = 0.6, lowest score used = 8.2; Agilent technologies 2200 Tapestation, RNA 604 
Screen Tape). Libraries for cluster generation and DNA sequencing were prepared 605 
following (Fisher et al., 2011), using Illumina TruSeq RNA library Preparation Kit v2. 606 
Libraries were run on the Next Seq 500 platform (Illumina) using the High Output 75 607 
cycles kit (2x36 cycles, paired end reads, single index). 608 
For RT-qPCR, RNA was quantified using a NanoDrop 2000c Spectrophotometer. 609 
cDNA was synthesised using the High-Capacity cDNA reverse transcription kit 610 
(Applied Biosystems), according to the manufacturer’s recommendations using a 611 
maximum of 2 µg RNA per 20 µL final volume. Quanta SYBR green Master Mix (Low 612 
ROX, Fermentas) was used following the manufacturer’s instructions. Data were 613 
obtained and analysed using the Applied Biosystems 7500 software. Results 614 
represent four independent replicates ± SEM. Expression of target genes was 615 
measured and normalized to rpl32 using standard curves. 616 
Western blot 617 
Protein was extracted from 12 adult female Drosophila midguts dissected in ice cold 618 
PBS. The tissues were lysed in 20 µL RIPA buffer (Sigma) using a microcentrifuge 619 
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pestle. Samples were spun down at 13,000 rpm for 10 minutes at 4°C and the 620 
supernatant was collected. Protein concentration was determined using Bradford 621 
reaction (Abcam) following the manufacturer’s recommendations. 40 µg of total 622 
protein was loaded onto NuPAGE 10% Bis-Tris gel (Thermo Fisher Scientific) and 623 
run using NuPAGE MOPS buffer (Thermo Fisher Scientific). Protein was transferred 624 
to a membrane (Bio-Rad) using the Trans-Blot Turbo system (Bio-Rad) following the 625 
manufacturer’s instructions. Membranes were blocked overnight at 4°C in 5% BSA 626 
(Sigma) then probed using pERK and tERK antibodies (Cell signalling) at 1:1000 627 
concentration. Antibody signal was detected using the SuperSignal West Pico 628 
Chemiluminescent Substrate (Thermo Fisher Scientific) system. 629 
Cell culture 630 
HMT-3522 T4-2 (V. Weaver, UCSF) cells were cultured in precoated collagen plates 631 
using DMEM / Ham's F12 (1:1) medium supplemented with 2mM Glutamine (Life 632 
Technologies), 250ng/ml insulin solution from bovine pancreas (Sigma-Aldrich), 10 633 
µg/ml transferrin (Sigma-Aldrich), 2.6 ng/mL Sodium selenite (Sigma-Aldrich), 10-10M 634 
17 beta-estradiol (Sigma-Aldrich), 1.4 x 10-6M hydrocortisone (Sigma-Aldrich), and 635 
10 ng/ml human prolactin (Miltenyi Biotec). 636 
3D acini were grown as follows: single cell suspensions (1.5 x 104 cells per ml) were 637 
plated in the appropriate medium supplemented with 2% Growth Factor Reduced 638 
Matrigel (GFRM; BD Biosciences). 100μl of this mix were added per well in a 96 well 639 
ImageLock plate (Essen Biosciences) precoated with 10μl of pure GFRM for 15 640 
minutes at 37 ºC. Cells were incubated at 37 ºC for 5 days, changing the media 641 
every two days, before IF. 642 
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For inhibitor studies, cells were treated from the time of plating with Tyrphostin-643 
AG1478 (80 nM in ethanol, Sigma-Aldrich), Erlotinib (100 nM in DMSO), and Ethanol 644 
or DMSO as appropriate controls, respectively. 645 
HEK293-FT (Thermo Fisher Scientific) were cultured in DMEM supplemented with 646 
10% FBS, 6mM L-glutamine and 0.1mM Non-Essential Amino Acids (NEAA) (all 647 
reagents from Life Technologies/Thermo Fisher).  648 
Generation of stable cell lines 649 
Stable cell lines were performed by co-transfecting HEK293-FT packaging cells with 650 
a pLKO.1-puromycin shRNA plasmid with VSVG and SPAX2 lentiviral packaging 651 
vectors using Lipofectamine 2000 according to the manufacturer's instructions 652 
(Invitrogen). Viral supernatants were collected; filtered using PES 0.45μm syringe 653 
filters (Starlab), and concentrated using Lenti-X Concentrator (Clontech) as per the 654 
manufacturer’s instructions. Cells were then transduced with the lentivirus for 3 days 655 
before selection with 1μg/ml puromycin (Thermo Fisher Scientific). shRNA target 656 
sequences: non-targeting control shScr (5’CCGCAGGTATGCACGCGT3’), shRalA 657 
(5’GGAGGAAGTCCAGATCGATAT3’), and shRalB (5’ 658 
CAAGGTGTTCTTTGACCTAAT3’). To knockdown RAL protein expression in H1229 659 
cells, cells were transfected with Dharmacon ON-TARGETplus siRNAs using the 660 
Amaxa Nucleofector system (Lonza).   661 
RNA extraction and RT-qPCR in cell culture samples 662 
RT-qPCR on human samples was performed following the same protocol used for 663 
Drosophila samples, except using human β-actin or GAPDH to normalise transcript 664 
levels using the delta-delta-CT method. 665 
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Cyst growth assay 666 
Acini labelling was adapted from previously described protocols. Briefly, cultures 667 
were fixed in 4% paraformaldehyde (PFA, Affimetrix) for 10 min at room temperature 668 
(RT), washed twice in PBS, blocked for 1 h in PFS buffer (PBS, 0.7% w/v fish skin 669 
gelatin (Sigma-Aldrich), 0.5% saponin (Sigma-Aldrich), and incubated with primary 670 
antibodies diluted in PFS at 4°C overnight with gentle rocking. Then, cyst cultures 671 
were washed three times with PFS and incubated with secondary antibodies diluted 672 
in PFS for 1h at RT, followed by washing twice in PFS and twice in PBS. Labelling 673 
was performed using Phalloidin (1:200) (Invitrogen) and Hoescht to label nuclei (10 674 
μg ml−1). 675 
Acquisition of confocal images was performed using Opera Phenix Z9501 high-676 
content imaging system (PerkinElmer), imaging at least 10 optical sections every 2 677 
µM, imaging 25 fields at 20x. Images were analysed using Harmony imaging 678 
analysis software (PerkinElmer). 679 
Internalisation assay 680 
Internalisation assays were performed as described in (Roberts et al., 2001). Briefly, 681 
cells were surface labelled at 4°C with 0.13 mg/ml NHS-SS-biotin (Pierce) in PBS for 682 
30 min. Following surface labelling, cells were transferred to complete medium at 683 
37°C to allow internalization in the presence of 0.6mM primaquine for the indicated 684 
times. Biotin was then removed from the cell surface by treatment with the cell-685 
impermeable reducing agent MesNa. Cells were then lysed and the quantity of 686 
biotinylated receptors determined using a capture-ELISA. The following antibodies 687 
were used for capture-ELISA; clone VC5 (BDPharmingen, Cat 555651) for α5β1, 688 
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anti-CD71 (BDPharmingen, Cat 555534) for the TfnR, anti-HGFR (R&D Systems, 689 
Cat AF276) and anti-EGFR1 (BDPharmingen, Cat 555996). 690 
Statistical analysis 691 
GraphPad Prism 8 software was used for statistical analyses. Information on sample 692 
size, and statistical tests used for each experiment are indicated in the figure 693 
legends. 694 
Data availability 695 
All data underlying the findings of this study are included in the manuscript and 696 
supporting file. Source data files have been provided for all figures containing 697 
numeric data. The entire raw data set corresponding to the work in this paper will be 698 
publicly available at the time of publication from our institutional repository 699 
http://dx.doi.org/10.5525/gla.researchdata.1142. RNA sequencing data has been 700 
deposited in GEO (accession GSE162421) and can be accessed through 701 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162421). Custom scripts 702 
used for quantification are available at  Github: 703 
https://github.com/emltwc/TracheaProject/blob/master/Blind_scoring.ijm; 704 
https://github.com/emltwc/2018-Cell-Stem-Cell  and 705 
https://github.com/emltwc/EGFRProject . 706 
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Figure legends 728 
Figure 1. Ral GTPases are necessary and sufficient to induce EGFR/MAPK 729 
signalling in intestinal stem cells. 730 
A. Adult Drosophila wings from control animals and with posterior compartment 731 
knockdown of wg (wg-RNAi), Egfr (Egfr-RNAi) or RalA using one of two 732 
previously validated RNAi lines (RalA-RNAi(1)) or combined wg and Egfr 733 
knockdown (wg-RNAi +Egfr-RNAi). Scale bar = 500 µm 734 
B. Blind scoring of wing dysmorphia on a scale of 1-5. Numbers inside bars 735 
represent the total number of wings scored. Kruskal-Wallis test followed by 736 
Dunn’s multiple comparisons test. 737 
C. Heat map from transcriptomic analysis of adult whole midguts from mock 738 
treated and Ecc15 infected control animals (+) or following adult restricted 739 
knockdown of RalA (RalA-RNAi(1)) using the escargot-gal4, UAS-gfp driver 740 
(ISC/EB>). RNA was extracted from >25 whole midguts per replicate and 4 741 
biological replicates per genotype/per condition were processed for 742 
sequencing.  743 
D. RT-qPCR confirmation of genes associated with EGFR/MAPK signalling in 744 
whole midguts from genotypes and conditions as in C expressed relative to 745 
rpl32 levels. n (number of biological replicates) = 4, each dot represents an 746 
independent RNA sample from >25 midguts per sample. Two-way ANOVA 747 
followed by Sidak’s multiple comparisons test. 748 
E. Representative confocal images of Sox21a immunofluorescence staining 749 
(red/grey) of adult posterior midguts from Mock treated or Ecc15 infected wild 750 
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type control animals or following knockdown of RalA (RalA-RNAi(1)) in 751 
stem/progenitor cells using escargot-gal4, UAS-gfp (ISC/EB>; green).  752 
F. Quantification of average Sox21a staining intensity, within the nuclear 753 
compartment (DAPI positive) in midguts as in E. Two-way ANOVA followed by 754 
Sidak’s multiple comparisons test; n=number of z-stack confocal images 755 
quantified, each from an independent posterior midgut. 756 
G. Representative confocal images of pERK immunofluorescence staining 757 
(red/grey) of adult posterior midguts from Mock treated or Ecc15 infected 758 
control animals or following knockdown of RalA (RalA-RNAi(1)) within 759 
stem/progenitor cells (ISC/EB>; green).  760 
H. Quantification of average pERK staining intensity within the ISC/EB 761 
compartment (GFP positive) of midguts as in G. Two-way ANOVA followed by 762 
Sidak’s multiple comparisons test; n=number of z-stack confocal images 763 
quantified, each from an independent posterior midgut. 764 
I. Immunohistochemistry images of total (bottom panels) and pERK (top panels) 765 
in small intestinal regenerating crypts 3 days after whole body irradiation of 766 
control mice (left panels) or mice following conditional intestinal epithelial 767 
knockout of Rala or Ralb. Scale bar = 50 µm 768 
J. Quantification of the percentage of cells with pERK staining in regenerating 769 
small intestinal crypts as in I. n=number of mice, with >12 crypts quantified 770 
per animal, each dot represents the average percentage from a given mouse. 771 
One-way ANOVA followed by Tukey’s multiple comparisons test. 772 
K. Representative confocal images of Sox21a immunofluorescence staining 773 
(red/grey) of adult posterior midguts from control animals or animals 774 
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overexpressing wild type Rala within stem/progenitor cells (ISC/EB>; green). 775 
Scale bar = 50 µm 776 
L. Quantification of average Sox21a staining intensity, within the nuclear 777 
compartment (DAPI positive; blue) of midguts as in K. Student’s t-test; 778 
n=number of z-stack confocal images quantified, each from an independent 779 
posterior midgut. 780 
M. Representative confocal images of pERK immunofluorescence staining 781 
(red/grey) in control animals or animals overexpressing wild type Rala within 782 
stem/progenitor cells (ISC/EB>; green).  783 
N. Quantification of average pERK staining intensity, within the ISC/EB 784 
compartment (GFP positive) of midguts as in M. Student’s t-test; n=number of 785 
z-stack confocal images quantified, each from an independent posterior 786 
midgut. 787 
Where indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns: not 788 
significant. All error bars represent SD. Scale bars = 20 µm, unless 789 
otherwise stated. 790 
Figure 1—figure supplement 1. Ral GTPases are necessary and sufficient to 791 
induce EGFR/MAPK signalling in intestinal stem cells. 792 
A. Representative confocal images of Sox21a immunofluorescence staining 793 
(red/grey) of adult posterior midguts from Mock treated or Ecc15 infected 794 
control animals or following knockdown of RalA using an independent RNAi 795 
line from that in Figure 1 (RalA-RNAi(2)) in stem/progenitor cells using 796 
escargot-gal4, UAS-gfp (ISC/EB>; green). Scale bar = 50 µm 797 
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B. Quantification of average Sox21a staining intensity, within the nuclear 798 
compartment (DAPI positive; blue) in midguts as in A. Two-way ANOVA 799 
followed by Sidak’s multiple comparisons test; n=number of z-stack confocal 800 
images quantified, each from an independent posterior midgut. 801 
C. Representative confocal images of pERK immunofluorescence staining 802 
(red/grey) of adult posterior midguts from Mock treated or Ecc15 infected 803 
control animals or following knockdown of RalA using an independent RNAi 804 
line from that in Figure 1 (RalA-RNAi(2)) within stem/progenitor cells 805 
(ISC/EB>; green).  806 
D. Quantification of average pERK staining intensity within the ISC/EB 807 
compartment (GFP positive) of midguts as in C. Two-way ANOVA followed 808 
by Sidak’s multiple comparisons test; n=number of z-stack confocal images 809 
quantified, each from an independent posterior midgut. 810 
E. Quantification of the percentage of cells with total ERK staining (tERK) in 811 
regenerating small intestinal crypts as in Figure 1I. n=number of mice, with 812 
>12 crypts quantified per animal, each dot represents the average 813 
percentage from a given mouse. One-way ANOVA followed by Tukey’s 814 
multiple comparisons test. 815 
F. Representative confocal images of tERK immunofluorescence staining 816 
(red/grey) in control animals or animals overexpressing wild type Rala within 817 
stem/progenitor cells (ISC/EB>; green). 818 
G. Quantification of average tERK staining intensity, within the ISC/EB 819 
compartment (GFP positive) of midguts as in F. Student’s t-test; n=number of 820 




H. Western blot of pERK and tERK from Control (Mock treated), wild type Rala 823 
overexpressing (Mock treated) and Ecc15 infected midguts and whole fly 824 
lysates. 825 
I. Representative confocal images of tERK immunofluorescence staining 826 
(red/grey) in mock treated wild type control animals or animals infected with 827 
Ecc15. 828 
J. Quantification of average tERK staining intensity, within the ISC/EB 829 
compartment (GFP positive) of midguts as in I. Student’s t-test; n=number of 830 
z-stack confocal images quantified, each from an independent posterior 831 
midgut. 832 
Where indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns: not significant. 833 
All error bars represent SD. Scale bars = 20 µm, unless otherwise stated. 834 
 835 
Figure 2. Ral GTPase activation is necessary for EGFR/MAPK signalling in 836 
regenerating ISCs/EBs. 837 
A. Representative confocal images of pH3 staining (red) within the ISC/EB 838 
compartment (green) in mock-treated or regenerating posterior midguts. Scale 839 
bar = 50 µm. 840 
B. Quantification of pH3 positive nuclei in control or GEFmeso-RNAi posterior 841 
midguts as in A. Two-way ANOVA followed by Sidak’s multiple comparisons 842 
test. n= number of midguts. 843 
C. Quantification of pH3 positive nuclei in control or RalGPS-RNAi posterior 844 
midguts as in A. Two-way ANOVA followed by Sidak’s multiple comparisons 845 
test. n=number of midguts. 846 
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D. Quantification of pH3 positive nuclei in control or Rgl-RNAi posterior midguts 847 
as in A. Two-way ANOVA followed by Sidak’s multiple comparisons test. 848 
n=number of midguts. 849 
E. Representative confocal images of pERK staining (red/grey) in mock-treated 850 
or regenerating control animals or animals with knockdown of GEFmeso, 851 
RalGPS or Rgl within the ISC/EB compartment (green). Scale bar = 20 µm. 852 
F. Quantification of average pERK staining intensity within the ISC/EB 853 
compartment (GFP positive) as in E. Two-way ANOVA followed by Sidak’s 854 
multiple comparisons test; n=number of z-stack confocal images quantified, 855 
each from an independent posterior midgut. 856 
Where indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns: not 857 
significant. All error bars represent SD. Scale bars = 20 µm, unless otherwise 858 
stated. 859 
Figure 3. Ral GTPases are required for EGFR/MAPK signalling upstream of 860 
Ras. 861 
A. Representative confocal images of pH3 staining (red) within the ISC/EB 862 
compartment (green) of control animals or animals overexpressing wild type 863 
Egfr (EGFRWT) or one of two constitutive Ras constructs used in this paper 864 
(RasV12(2)) with or without RalA knock-down within stem/progenitor cells 865 
(ISC/EB>; green). Scale bar = 50 µm. 866 
B. Quantification of pH3 positive nuclei in posterior midguts, as in A. Two-way 867 
ANOVA followed by Sidak’s multiple comparisons test. n=number of midguts. 868 
C. Representative confocal images of pERK staining (red/grey) of control 869 
animals or animals overexpressing wild type Egfr (EGFRWT) or one of two 870 
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constitutive Ras constructs used in this paper (RasV12(2)) with or without RalA 871 
knock-down within stem/progenitor cells (ISC/EB>; green).  872 
D. Quantification of average pERK staining intensity, as seen in (C), within the 873 
ISC/EB compartment (GFP positive). Two-way ANOVA followed by Sidak’s 874 
multiple comparisons test; n=number of z-stack confocal images quantified, 875 
each from an independent posterior midgut. 876 
E. Representative confocal images of pH3 staining (red) within the ISC/EB 877 
compartment (green) of control animals or animals overexpressing two types 878 
of constitutively active Egfr constructs (EGFRλtop or EGFRA887T) with or without 879 
RalA knock-down within stem/progenitor cells (ISC/EB>; green). Scale bar = 880 
50 µm.  881 
F. Quantification of pH3 positive nuclei in posterior midguts, as in E. Two-way 882 
ANOVA followed by Sidak’s multiple comparisons test. Error bars represent 883 
SEM. n=number of midguts. 884 
G. Representative confocal images of pERK staining (red/grey) within the 885 
ISC/EB compartment (green) of control animals or animals overexpressing 886 
two types of constitutively active Egfr constructs (EGFRλtop or EGFRA887T) with 887 
or without RalA knock-down within stem/progenitor cells (ISC/EB>; green).  888 
H. Quantification of average pERK staining intensity, as in G, within the ISC/EB 889 
compartment (GFP positive). Two-way ANOVA followed by Sidak’s multiple 890 
comparisons test; n=number of z-stack confocal images quantified, each from 891 
an independent posterior midgut. 892 
Where indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns: not 893 




Figure 3—figure supplement 1. Ral GTPases are required for EGFR/MAPK 896 
signalling upstream of Ras. 897 
A. Percentage survival of adult flies eclosing with the desired experimental 898 
genotype. Fisher’s exact test. 899 
B. Adult Drosophila wings from control animals and with posterior compartment 900 
overexpression of wild type Egfr (EGFRWT) with or without knockdown of RalA 901 
(RalA-RNAi(1)). Scale bar = 500 µm 902 
C. Representative confocal images of pH3 staining (red/grey; white arrows) 903 
within the ISC/EB compartment (green) in animals overexpressing a 904 
constitutively active Ras transgene independent from that in Figure 3 905 
(RasV12(1)) with or without RalA knock-down (RalA-RNAi(2)) within 906 
stem/progenitor cells (ISC/EB>; green). Scale bar = 50 µm.  907 
D. Quantification of pH3 positive nuclei in posterior midguts, as in C. Data were 908 
analysed by Student’s t-test. n=number of midguts. 909 
E. Representative confocal images of tERK staining (red/grey) in animals 910 
overexpressing wild type Egfr (EGFRWT) with or without RalA knock-down 911 
within stem/progenitor cells (ISC/EB>; green). Scale bar= 20 µm  912 
F. Quantification of average tERK staining intensity within the ISC/EB 913 
compartment (GFP positive) of midguts as in E. Student’s t-test. n=number of 914 
z-stack confocal images quantified, each from an independent posterior 915 
midgut. 916 
Where indicated: ****p<0.0001, ns: not significant. All error bars represent 917 




Figure 4. Ral GTPases are required for EGFR internalisation. 920 
A. Representative images of wild type EGFR staining (red/turbo colourmap) in 921 
adult Drosophila midgut stem/progenitor cells (ISC/EB>; green) without 922 
(Control) or with RalA knock-down (RalA-RNAi).  923 
B. Quantification of EGFR plasma membrane staining localisation in midguts as 924 
in A, relative to the cytoplasm. Data is presented as Tukey's box and whiskers 925 
plot. Data were analysed by Student’s t-test. n=number of z-stack confocal 926 
images quantified, each from an independent posterior midgut. 927 
C. Representative images of EGFRA887T staining (red/turbo colourmap) in adult 928 
Drosophila midgut stem/progenitor cells (ISC/EB>; green) without (control) or 929 
with RalA knock-down (RalA-RNAi).  930 
D. Quantification of EGFRA887T plasma membrane staining localisation as in C, 931 
relative to the cytoplasm presented as Tukey's box and whiskers plot. 932 
Student’s t-test. n=number of z-stack confocal images quantified, each from 933 
an independent posterior midgut. 934 
E. Representative images of EGFR staining in (red/turbo colourmap) in adult 935 
Drosophila midgut stem/progenitor cells (ISC/EB>; green) without (control) or 936 
with wild type RalA overexpression (RalAwt).  937 
F. Quantification of EGFR plasma membrane staining localisation in midguts as 938 
in E, relative to the cytoplasm. Data is presented as Tukey's box and whiskers 939 
plot. Student’s t-test. n= number of z-stack confocal images quantified, each 940 
from an independent posterior midgut. 941 
G. Internalisation of EGFR over time determined by a surface biotinylation ELISA 942 
based assay in H1299 human non-small cell lung cancer cells transfected 943 
with a non-targeting (Control) or combined Rala and Ralb knockdown 944 
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constructs (siRala+b) and incubated in the presence or absence of EGF 945 
ligand. Data from one experiment with three technical replicates and 946 
representative of three independently performed experiments is presented. 947 
Two-way ANOVA followed by Bonferroni's multiple comparisons test. Error 948 
bars represent SEM.  949 
Where indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. All error bars 950 
represent SD. Scale bars = 20 µm. 951 
Figure 4—figure supplement 1. Demonstration of method used to quantify 952 
EGFR cellular localisation. 953 
A. Example of a single confocal plane from a Z-stack confocal image used for 954 
the quantification of EGFR localisation. Stem/progenitor cells are identified 955 
using escargot-gal4, UAS-gfp (ISC/EB>; green), nuclei are highlighted by 956 
DAPI staining (blue). These layers are converted to binary masks based on 957 
the triangle method to determine the threshold value and subjected to 958 
morphological operations to yield masks for the quantification of EGFR 959 
intensity in the various subcellular locations. The membrane compartment 960 
(red) is defined as the dilated outline of the ISC/EB compartment. The 961 
cytoplasmic compartment (green) is defined as the ISC/EB compartment 962 
minus the membrane and nuclear (blue) compartments. 963 
B. Coloured bar representing the colour of pixels with a given 16-bit intensity in 964 
the turbo colourmap. 965 
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Figure 4—figure supplement 2. Ras is required for EGFR internalisation. 966 
A. Representative images of wild type EGFR staining (red/turbo colourmap) in 967 
adult Drosophila midgut stem/progenitor cells (ISC/EB>; green) without 968 
(Control) or with Ras knock-down (Ras-RNAi).  969 
B. Quantification of EGFR plasma membrane staining localisation in midguts as 970 
in A, relative to the cytoplasm. Data is presented as Tukey's box and whiskers 971 
plot. Student’s t-test. n=number of z-stack confocal images quantified, each 972 
from an independent posterior midgut. 973 
Where indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. All scale bars = 974 
20 µm. 975 
Figure 4—figure supplement 3. RAL GTPases are required for EGFR 976 
internalisation. 977 
A. Confirmation of knock-down of Rala in H1299 human non-small cell lung 978 
cancer cells transfected with a non-targeting (Control) or combined Rala 979 
and Ralb knockdown constructs (siRala+b). Data expressed as Delta CT 980 
using GAPDH as a reference. n = 3 repeat knockdown cultures. Student's 981 
t-test. Error bars represent SEM. 982 
B. Confirmation of knock-down of Ralb in H1299 human non-small cell lung 983 
cancer cells transfected with a non-targeting (Control) or combined Rala 984 
and Ralb knockdown constructs (siRala+b). Data expressed as Delta CT 985 
using GAPDH as a reference. n = 3 repeat knockdown cultures. Student's 986 
t-test. Error bars represent SEM. 987 
C. Internalisation of cMet over time as determined by a surface biotinylation 988 
ELISA based assay in H1299 human non-small cell lung cancer cells 989 
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transfected with a non-targeting (Control) or combined Rala and Ralb 990 
knockdown constructs (siRala+b) and incubated in the presence or 991 
absence of HGF ligand. Data from one representative experiment is 992 
shown with three technical replicates. Experiment was repeated three 993 
times. Two-way ANOVA followed by Bonferroni's multiple comparisons 994 
test. Error bars represent SEM. 995 
D. Internalisation of cMet over time as determined by a surface biotinylation 996 
ELISA based assay in H1299 human non-small cell lung cancer cells 997 
transfected with a non-targeting (Control) or combined Rala and Ralb 998 
knockdown constructs (siRala+b) and incubated in the presence or 999 
absence of EGF ligand. Data from one representative experiment is shown 1000 
with three technical replicates. Experiment was repeated three times. Two-1001 
way ANOVA followed by Bonferroni's multiple comparisons test. Error bars 1002 
represent SEM. 1003 
E. Internalisation of human Transferrin receptor (hTfnR) over time as 1004 
determined by a surface biotinylation ELISA based assay in H1299 human 1005 
non-small cell lung cancer cells transfected with a non-targeting (Control) 1006 
or combined Rala and Ralb knockdown constructs (siRala+b) and 1007 
incubated in the presence or absence of EGF ligand. Data from one 1008 
representative experiment is shown with three technical replicates. 1009 
Experiment was repeated three times. Two-way ANOVA followed by 1010 
Bonferroni's multiple comparisons test. Error bars represent SEM. 1011 
F. Internalisation of α5β1 integrin over time as determined by a surface 1012 
biotinylation ELISA based assay in H1299 human non-small cell lung 1013 
cancer cells transfected with a non-targeting (Control) or combined Rala 1014 
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and Ralb knockdown constructs (siRala+b) and incubated in the presence 1015 
or absence of EGF ligand. Data from one representative experiment is 1016 
shown with three technical replicates. Experiment was repeated three 1017 
times. Two-way ANOVA followed by Bonferroni's multiple comparisons 1018 
test. Error bars represent SEM. 1019 
Where indicated: ***p<0.001 1020 
Figure 5. Ral GTPases mediate malignant transformation of the intestinal and 1021 
mammary epithelium. 1022 
A. Representative confocal images of pH3 staining (red/grey) in midguts 1023 
overexpressing Src-kinase (Src64wt) with or without Rala knock-down (RalA-1024 
RNAi(2)) in stem/progenitor cells (ISC/EB>; green). White arrows indicate pH3 1025 
positive nuclei.  1026 
B. Quantification of pH3 positive nuclei in posterior midguts as in A. Data were 1027 
analysed by Student’s t-test. n= number of midguts. 1028 
C. Representative confocal images of Sox21a staining (red/grey) in midguts 1029 
overexpressing Src-kinase (Src64wt) with or without Rala knock-down (RalA-1030 
RNAi(2)) in stem/progenitor cells (ISC/EB>; green). Scale bar = 50 µm. 1031 
D. Quantification of average Sox21a staining intensity within the nuclear 1032 
compartment (DAPI positive) as in C. Two-way ANOVA followed by Sidak’s 1033 
multiple comparisons test; n=number of z-stack confocal images quantified, 1034 
each from an independent posterior midgut.  1035 
E. Representative confocal images of pERK staining (red/grey) in midguts 1036 
overexpressing Src-kinase (Src64wt) with or without Rala knock-down (RalA-1037 
RNAi(2)) in stem/progenitor cells (ISC/EB>; green).  1038 
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F. Quantification of average pERK staining intensity within the ISC/EB 1039 
compartment (GFP positive) as in E. Two-way ANOVA followed by Sidak’s 1040 
multiple comparisons test; n=number of z-stack confocal images quantified, 1041 
each from an independent posterior midgut. Error bars represent SD. 1042 
G. Representative images of EGFR staining (red/grey) in midguts 1043 
overexpressing Src-kinase (Src64wt) and EGFRwt with or without Rala knock-1044 
down (RalA-RNAi(2)) in stem/progenitor cells (ISC/EB>; green).  1045 
H. Quantification of EGFR plasma membrane staining localisation relative to the 1046 
cytoplasm as in G presented as Tukey's box and whiskers plot. Data were 1047 
analysed by Student’s t-test. n=number of z-stack confocal images quantified, 1048 
each from an independent posterior midgut. 1049 
I. Confocal fluorescence microscopy images of HMT3522 T4-2 3D cultures, 1050 
treated with EGFR inhibitors (tyrphostin AG1478 and erlotinib) or 1051 
corresponding vehicle controls (ethanol and DMSO, respectively) followed by 1052 
fixation after 5 days and staining for F-actin (yellow) and nuclei (blue, 1053 
Hoechst). Scale bar = 40 µm. 1054 
J. Quantification of area of 5-days T4-2 cysts treated as in I. n ≥ 1214 cysts 1055 
assessed from four wells/condition/experiment, two independent experiments. 1056 
One-way ANOVA, Tukey’s multiple comparisons test. 1057 
K. Confocal fluorescence microscopy images of HMT3522 T4-2 cysts of 5-days 1058 
expressing either scramble, RalA or RalB shRNA. Cysts were fixed and 1059 
stained for F-actin (yellow) and nuclei (blue, Hoechst). Scale bar = 40 µm. 1060 
L. Quantification of 5-days T4-2 cysts as in K.  n ≥ 468 cysts assessed from four 1061 
wells/condition/experiment, three independent experiments. One-way 1062 
ANOVA, Tukey’s multiple comparisons test. 1063 
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Where indicated: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, ns: not 1064 
significant. All error bars represent SD. Scale bars = 20 µm, unless otherwise 1065 
stated. 1066 
Figure 5—figure supplement 1. Ral knockdown in human mammary cell lines.  1067 
A. Confirmation of knock-down of Rala in HMT3522 T4-2 3D cultures in parental 1068 
lines or following shScr, shRala and shRalb transfection. Data expressed as 1069 
Delta CT using ACTB as a reference. n = 3 independent samples, Error bars 1070 
represent SEM. Data was analysed using One-way ANOVA followed by 1071 
Tukey's multiple comparisons test. 1072 
B. Confirmation of knock-down of Ralb in HMT3522 T4-2 3D cultures in parental 1073 
lines or following shScr, shRala and shRalb transfection. Data expressed as 1074 
Delta CT using ACTB as a reference.  n = 3 independent samples, Error bars 1075 
represent SEM. Data was analysed using One-way ANOVA followed by 1076 
Tukey's multiple comparisons test. 1077 
Where indicated: ***p<0.001, ****p<0.0001. 1078 
Figure 6. Working model depicting the role of RAL GTPases in EGFR/MAPK 1079 
signalling. 1080 
A. Experimental contexts used. Most results were acquired from Drosophila 1081 
intestinal epithelial stem-progenitor cells. Key findings were confirmed using 1082 
mammalian intestine and human lung and breast cancer cell lines. 1083 
B. RalA is necessary for EGFR internalisation and MAPK activation leading to 1084 




Supplementary File 1. Full genotype list. Table containinng a list of all Drosophila 1087 
genotypes used in the paper.  1088 
  1089 
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